Zhitong Finance App News, Hanson Pharmaceuticals (03692.HK) announced that the Group's innovative drug, ametinib (ametinib mesylate tablets), has obtained a drug registration certificate issued by the China National Drug Administration (NMPA), and approved the addition of “for use in II-IIIB stage with epidermal growth factor receptor (“EGFR”) exon 19 deletion or exon 21 (L858R) replacement mutation. Patients must have previously undergone resection surgery and treatment. It is up to the doctor to accept or not to receive adjuvant chemotherapy” Adaptation disease. This is the fourth approved indication for Amelox®.

Zhitongcaijing · 6d ago
Zhitong Finance App News, Hanson Pharmaceuticals (03692.HK) announced that the Group's innovative drug, ametinib (ametinib mesylate tablets), has obtained a drug registration certificate issued by the China National Drug Administration (NMPA), and approved the addition of “for use in II-IIIB stage with epidermal growth factor receptor (“EGFR”) exon 19 deletion or exon 21 (L858R) replacement mutation. Patients must have previously undergone resection surgery and treatment. It is up to the doctor to accept or not to receive adjuvant chemotherapy” Adaptation disease. This is the fourth approved indication for Amelox®.